Menu
ÚHKT

Impaktované publikace

[21]

Koenecke, C.; Heim, D.; van Biezen, A.; Heuser, M.; Aljurf, M.; Kyrcz-Krzemien, S.; Volin, L.; de Souza, C.A.; Gedde-Dahl, T.; Sengeloev, H.; Schanz, U.; Komarnicki, M.; Arroyo, C.H.; Tholouli; E.; Gluckman, E.; Esquirol, A.; Yakoub-Agha, I.; Gürman, G.; Olavarria, E.; Kröger, N.; Rovira, M.; Kahls, P.; Alegre, A.; Nemet, D.; Stamatovic, D.; Vítek, A.; et. al.

Outcome of patients with chronic myeloid leukemia and a low-risk score: allogeneic hematopoietic stem cell transplantation in the era of targeted therapy: a report from the EBMT chronic malignancies working party

[rok vydání 2017, impact factor 3.874 ]

[22]

Bazarbachi, A.; Labopin, M.; Angelucci, E.; Gulbas, Z.; Ozdogu, H.; Arat, M.; de Rosa, L.; Pastano, R.; Pioltelli, P.; Montserrat, R.; Martino, M.; Ciceri, F.; Koç, Y.; Socie, G.; Blaise, D.; Herrera, C.; Chalandon, Y.; Bernasconi, P.; Marotta, G.; Castagna, L.; McDonald, A.; Visani, G.; Carluccio, P.; Vitek, A.; et al.

Haploidentical transplantation with post-transplantation cyclophosphamide for T cell acute lymphoblastic leukemia: a report from the European Society for Blood and Marrow Transplantation Acute Leukemia Working Party

[rok vydání 2020, impact factor 3.853 ]

[23]

McLornan, D.; Szydlo, R.; Koster, L.; Chalandon, Y.; Robin, M.; Wolschke, C.; Beelen, D.; Socié, G.; Bornhäuser, M.; Angelucci, E.; Niederwieser, D.; Gerbitz, A.; Finke, J.; Vitek, A.; et al.

Myeloablative and reduced-intensity conditioned allogeneic hematopoietic stem cell transplantation in myelofibrosis: a retrospective study by the chronic malignancies working party of the European society for blood and marrow transplantation

[rok vydání 2019, impact factor 3.853 ]

[24]

Raj, K.; Eikema, D.-J.; McLornan, D.P.; Olavarria, E.; Blok, H.-J.; Bregante, S.; Ciceri, F.; Passweg, J.; Ljungman, P.; Schaap, N.; Carlson, K.; Zuckerman, T.; de Wreede, L.C.; Volin, L.; Koc, Y.; Diez-Martin, J.L.; Brossart, P.; Wolf, D.; Blaise, D.; Bartolomeo, P.D.; Vitek, A.; et al.

Family mismatched allogeneic stem cell transplantation for myelofibrosis: report from the chronic malignancies working party of European society for blood and marrow transplantation

[rok vydání 2019, impact factor 3.853 ]

[25]

Andersen, N.S.; Bornhäuser, M.; Gramatzki, M.; Dreger, P.; Vitek, A.; et al.

Reduced intensity conditioning regimens including alkylating chemotherapy do not alter survival outcomes after allogeneic hematopoietic cell transplantation in chronic lymphocytic leukemia compared to low-intensity non-myeloablative conditioning

[rok vydání 2019, impact factor 3.656 ]

[26]

Cremers, E.M.; van Biezen, A.; de Wreede, L.; Scholten, M.; Vitek, A.; Finke, J.; Platzbecker, U.; Beelen, D.; Schwerdtfeger, R.; Volin, L.; Harhalakis, N.; Blijlevens, N.; Nagler, A.; Kröger, N.; de Witte, T.

Prognostic pre-transplant factors in myelodysplastic syndromes primarily treated by high dose allogeneic hematopoietic stem cell transplantation: a retrospective study of the MDS subcommittee of the CMWP of the EBMT

[rok vydání 2016, impact factor 3.083 ]

[27]

Giebel, S.; Labopin, M.; Holowiecki, J.; Labar, B.; Komarnicki, M.; Koza, V.; Masszi, T.; Mistrik, M.; Lange, A.; Hellmann, A.; Vitek, A.; Pretnar, J.; Mayer, J.; Rzepecki, P.; Indrak, K.; Wiktor-Jedrzejczak, W.; Wojnar, J.; Krawczyk-Kulis, M.; Kyrcz-Krzemien, S.; Rocha, V.

Outcome of HLA-matched related allogeneic hematopoietic stem cell transplantation for patients with acute leukemia in first complete remission treated in Eastern European centers : better results in recent years

[rok vydání 2009, impact factor 2.919]

[28]

Pohlreich, D.; Vitek, A.; Maalouf, J.; Cetkovsky, P.

Decreased risk of acute gastrointestinal toxicity when substituting methotrexate with mycophenolate mofetil in the prevention of graft-versus-host disease in stem cell transplantation following myeloablative conditioning regimens

[rok vydání 2007, impact factor 2.621]

[29]

Pumannova, M.; Roubalova, K.; Vitek, A.; Sajdova, J.

Comparison of quantitative competitive polymerase chain reaction-enzyme-linked immunosorbent assay with LightCycler-based polymerase chain reaction for measuring cytomegalovirus DNA in patients after hematopoietic stem cell transplantation

[rok vydání 2007, impact factor 2.553]

[30]

Marková, J.; Michková, P.; Burčková, K.; Březinová, J.; Michalová, K.; Dohnalová, A.; Soukupová Maaloufová, J.; Soukup, P.; Vítek, A.; Cetkovský, P.; Schwarz, J.

Prognostic impact of DNMT3A mutations in patients with intermediate cytogenetic risk profile acute myeloid leukemia

[rok vydání 2011, impact factor 2.548 ]

[31]

Válková, V.; Schwarz, J.; Vítek, A.; Marková, M.; Pohlreich, D.; Benešová, K.; Michalová, K.; Cetkovský, P.; Trněný, M.

The effect of allogeneic stem cell transplantation on high risk chronic lymphocytic leukaemia: a single centre retrospective analysis

[rok vydání 2010, impact factor 2.475]

[32]

Moravcová, J.; Nádvorníková, S.; Zmeková, V.; Michalová, K.; Březinová, J.; Lukášová, M.; Vítek, A.; Hrabánek, J.; Gašová, Z.; Sedláček, P.; Starý, J.

Molecular monitoring of responses to DLI and DLI + IFN treatment of post-SCT relapses in patients with CML

[rok vydání 2006, impact factor 2.333]

[33]

van Gelder, M.; Ziagkos, D.; de Wreede, L.; van Biezen, A.; Dreger, P.; Gramatzki, M.; Stelljes, M.; Andersen, N.S.; Schaap, N.; Vitek, A.; et al.

Baseline characteristics predicting very good outcome of allogeneic hematopoietic cell transplantation in young patients with high cytogenetic risk chronic lymphocytic leukemia: a retrospective analysis from the chronic malignancies working party of the EBMT

[rok vydání 2017, impact factor 2.308 ]

[34]

Vydra, J.; Válková, V.; Čemusová, B.; Kolář, M.; Nováková, L.; Soukup, P.; Šálek, C.; Vraná, M.; Pytlík, R.; Lesný, P.; Vítek, A.; Cetkovský, P.; Marková, M.

Hematopoietic stem cell transplantation from haploidentical donors in aplasia after cladribine/cytarabine chemotherapy for refractory acute myeloid leukemia or myelodysplastic syndrome

[rok vydání 2019, impact factor 2.298 ]

[35]

Dickinson, A.M.; Hromadníková, I.; Sviland, L.; Jackson, G.H.; Taylor, P.R.A.; Vavřinec, J.; Sedláček, P.; Čermáková, M.; Starý, J.; Vítek, A.; Sajdová, J.; Proctor, S.J.

Use of skin explant model for predicting GVHD in HLA-matched bone marrow transplants : effect of GVHD prophylaxis

[rok vydání 2006, impact factor 2.277]

[36]

Čermák, J.; Vítek, A.; Michalová, K.

Combined stratification of refractory anemia according to both WHO and IPSS criteria has a prognostic impact and improves identification of patients who may benefit from stem cell transplantation

[rok vydání 2006, impact factor 2.244]

[37]

Roubalova, K.; Strunecky, O.; Vitek, A.; Zufanova, S.; Prochazka, B.

Genetic variability of cytomegalovirus glycoprotein O in hematopoietic stem cell transplant recipients

[rok vydání 2011, impact factor 2.216 ]

[38]

Rožman, P.; Karas, M.; Kosir, A.; Labar, B.; Madrigal, A.; Middleton, P.; Navarrete, C.; Oudshoorn, M.; Schennach, H.; Vitek, A.; Bohinjec, M.

Are human platelet alloantigens (HPA) minor transplantation antigens in clinical bone marrow transplantation?

[rok vydání 2006, impact factor 2.172]

[39]

Matejkova, E.; Korinkova, P.; Suttnar, J.; Vitek, A.

Our experiences with 1D-IEF in selection of bone marrow donors

[rok vydání 2018, impact factor 2.111]

[40]

Roubalová, K.; Suchánková, A.; Vítek, A.; Sajdová, J.

Presence of herpes simplex virus (HSV) in peripheral leukocytes of patient who developed active HSV infection after bone marrow transplantation

[rok vydání 2006, impact factor 1.744]